Givaudan
This article was originally published in The Rose Sheet
Executive Summary
Fragrance and flavors supplier inaugurates new multipurpose plant for manufacturing of complex specialty ingredients discovered by the company's global fragrance research team in Dubendorf, Switzerland. Plant marks a "turning point" in strategy for Givaudan's fragrance ingredients business, signaling a move away from manufacturing commodity chemicals such as sunscreen filters to focus on producing molecules for "innovative and proprietary specialties," company notes. Project represents a quarter of the total annual investment of the fragrance division, firm adds. Earlier this year, Givaudan ended seven-year UV filter manufacturing relationship with Roche (1"The Rose Sheet" Jan. 20, 2003, In Brief). Separately, the firm announced hiring of Caroline Sabas as a perfumer. Sabas most recently worked for Fragrance Resources...
You may also be interested in...
Givaudan Fine Fragrance Growth Fueled By 2003 Launches
Givaudan's fine fragrance sales increased double digits in local currencies in 2003 driven by an increasing number of new launches, the fragrance supplier announced March 2
Parsol production
Roche Vitamins will transition production of its Parsol UV filters to LC United in Taiwan. Long-term agreement ends seven-year relationship with Givaudan. Parsol filters will cease production in Givaudan's Vernier, Switzerland facility by the end of 2003, Roche says. Agreement with LC United involves manufacture of the UVA/UVB filter Parsol 1789 and UVB filters Parsol, MCX, Parsol 5000, Parsol 340 and Parsol HS. Collaboration will provide Roche with opportunity to broaden its range of UV protection solutions, Roche adds. LC facility will deliver materials conforming to the existing Roche specifications, firm notes...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.